Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1803 in Relapsed/Refractory Multiple Myeloma
NCT06566547Phase 2Active, not recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of velinotamig in multiple myeloma (MM), sponsored by Zhixiang Jintai. Started Aug 2024; status: active, not recruiting.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06566547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566547.